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ABSTRACT 
Objective: Sodium (23Na)-MRI is an emerging imaging technique to investigate in-vivo 
changes in tissue viability, reflecting neuroaxonal integrity and metabolism. Using an 
optimised 23Na-MRI protocol with smaller voxel sizes and improved tissue contrast, we 
wanted to investigate whether brain total sodium concentration (TSC) is a biomarker long-
term disease outcomes in a cohort of patients with relapse-onset multiple sclerosis (MS), 
followed from disease onset. 
 
Methods: We performed a cross-sectional study in 96 patients followed up ~15 years after a 
clinically isolated syndrome (CIS), and 34 healthy controls. Disease course was classified as 
CIS, relapsing-remitting MS or secondary progressive MS. We acquired 1H-MRI and 23Na-
MRI, and calculated the TSC in cortical grey matter, deep grey matter, normal-appearing 
white matter and white matter lesions. Multivariable linear regression was used to identify 
independent associations of tissue-specific TSC with physical disability and cognition, with 
adjustment for tissue volumes. 
 
Results: TSC in all tissues was higher in MS patients compared with healthy controls and 
patients who remained CIS; with differences driven by secondary progressive MS patients. 
Higher cortical grey matter TSC was independently associated with Expanded Disability 
Status Scale (R2=0.26), timed 25-foot walk test (R2=0.23), 9-hole peg test (R2=0.23), Paced 
Auditory Serial Addition Test (R2=0.29), Symbol Digit Modalities Test (R2=0.31) and 
executive function (R2=0.36) test scores, independent of grey matter atrophy.  
 
Conclusions: Sodium accumulation in cortical grey matter reflects underlying neuroaxonal 
metabolic abnormalities relevant to disease course heterogeneity and disability in relapse-
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onset MS. TSC and should be considered as an outcome measure in future neuroprotection 
trials. 
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INTRODUCTION 
Energy failure is thought to be central to the pathophysiology of multiple sclerosis (MS), and 
may provide a link between demyelination and neurodegeneration1, the two pathological 
hallmarks of MS. Following inflammatory demyelination, compensatory electrophysiological 
changes occur in demyelinated axons in order to preserve function, at least in the short-
term, with up-regulation and redistribution of sodium channels in order to maintain 
conduction.2 The high energy requirements of the Na+/K+-ATPase pump, potentially 
compounded by primary mitochondrial dysfunction in MS3, overwhelm neuronal ATP 
production, resulting in failure of the Na+/K+-ATPase pump and intracellular sodium 
accumulation. Increased intracellular sodium concentration triggers a cascade of events that 
ultimately results in neuroaxonal loss, the major substrate for disease progression in MS. 
 
Sodium (23Na) MRI is an emerging imaging technique able to quantify brain tissue sodium 
concentration in-vivo, providing information on tissue viability, reflecting neuroaxonal integrity 
and metabolic function.4 5 The measured total sodium concentration (TSC) using 23Na-MRI 
reflects a composite of intracellular sodium (10-15mM) and extracellular sodium (~140mM). 
Previous 23Na-MRI studies have found evidence of increased TSC in white matter (WM) 
lesions and normal-appearing tissues in MS6-10, reflecting either increased intracellular 
sodium, expansion of the extracellular space (due to neuroaxonal loss), or both. In cross-
sectional studies, increases in TSC are most marked in progressive MS8 and in patients with 
greater physical disability7 8 and cognitive impairment10.  
 
23Na-MRI is challenging due to the lower tissue concentrations of sodium compared with 
hydrogen, and a lower signal-to-noise ratio. Previous studies have been affected by 
hardware/software limitations of clinical scanners and have acquired 23Na-MRI with large 
voxel sizes (4x4x4mm3)6-10, thereby increasing partial volume contamination, especially from 
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cerebrospinal fluid (CSF), which contains a higher sodium concentration (~140mM) than 
tissues. We recently optimised a 23Na-MRI protocol with smaller voxel size (3x3x3mm3 vs 
4x4x4mm3 in previous studies), and a 3D-cones acquisition trajectory technique with 
improved tissue contrast, signal-to-nose ratio and reproducibility, in clinically-acceptable 
scanning times.11  
 
We applied this optimised 23Na-MRI protocol in a cross-sectional study involving a unique 
and homogeneous cohort of patients followed over ~15 years following presentation with a 
clinically isolated syndrome (CIS). The aims of the study were: (1) to investigate the 
relationship of tissue TSC with long-term disease course in a group of patients well-matched 
for disease onset and (2) to investigate the relationship of tissue TSC with physical disability 
and cognitive impairment.  
 
METHODS 
Patients 
This is a cross-sectional study carried out at the last visit of a longitudinal clinical-MRI study. 
Briefly, patients were initially recruited into the study within 3 months of a CIS and invited to 
return for scheduled clinical and MRI follow-up, irrespective of clinical status.12 The clinical 
and MRI assessments presented here were done ~15 years after CIS. We diagnosed MS 
using the McDonald 2010 criteria at follow-up.13 Disease course at ~15 years was classified 
as CIS, relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS).14 We 
retrospectively reviewed the clinical details and MRI scans of patients diagnosed as CIS in 
light of the revised McDonald 2017 criteria and no additional patients were identified as 
having MS. 
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We assessed physical disability using the Expanded Disability Status Scale (EDSS), timed 
25-foot walk test (TWT) and 9-hole peg test (9HPT).15 16 The TWT raw scores were 
transformed into an inverse to determine walking speed (in feet/second) and 9HPT times 
were transformed into a Z-score using normative values.16 Cognition was assessed using: 
(1) tests of verbal and visual memory from the Adult Memory and Information Processing 
Battery17; (2) tests of information processing speed, the Paced Auditory Serial Addition Test 
(PASAT)16 and the Symbol Digit Modalities Test (SDMT)18; and (3) tests of executive 
function, the Hayling and Brixton tests.19 Premorbid intellectual function was estimated using 
the National Adult Reading Test (NART).20 The raw test scores for each of the cognitive 
tests were transformed into a z-score using published age-matched normative data.16-19 
Patients with a z-score ≤ -2 were considered impaired on that test. Self-reported fatigue was 
measured using the Fatigue Severity Scale.21 None of the patients had a relapse or received 
treatment with corticosteroids within 3 months of the clinical assessment and MRI.  
 
A group of healthy control subjects with no known neurological disorder underwent the same 
MRI protocol. All subjects provided written informed consent and the study was approved by 
the institutional Research Ethics Committee. 
 
MRI acquisition  
The MRI scans were obtained on the same 3.0 T scanner (Achieva, Phillips Healthcare 
Systems). Using a 32-channel receiver head coil the following 1H-MRI scans were obtained: 
(i) a proton density(PD)/T2-weighted fast-spin multi-echo scan for identification of T2-
hyperintense lesions; (ii) a 2D T1-weighted spin echo scan for identification of T1-
hypointense lesions; and (iii) a magnetization-prepared 1mm3 isotropic 3D T1-weighted  
turbo field echo scan for tissue segmentation. The 32-channel head coil was changed to a 
23Na TX/RX volume body coil (RAPID Biomedical, Germany) and the subject was returned to 
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the scanner with two calibration agar phantoms placed in a pre-defined position, containing 
NaCl with a sodium concentration of 40mM and 80mM respectively. The NaCl concentration 
in the calibration phantoms was chosen to encompass the range of physiological values 
expected in brain parenchymal tissues. Following the 23Na-MRI with the subject remaining in 
the same position, a low-resolution 1H-PD/T2-weighted scan was obtained using the body 
coil, for registration purposes. Details of the MRI acquisition protocol are shown in 
Supplementary Table 1. Representative images from a healthy control subject and each of 
the patient groups studied is shown in Figure 1. 
 
Image analysis 
A single rater (WJB) manually outlined T2-hyperintense and T1-hypointense white matter 
lesions on using a semi-automated edge-finding tool (JIM6.0, Xinapse Systems, UK) to 
obtain T2 lesion volume (T2LV) and T1 lesion volume (T1LV). The T2-hyperintense lesion 
masks were co-registered to the 3D T1-weighted scan. White matter lesions were filled using 
a patch-based lesion filling technique.22 Brain extraction and probabilistic tissue 
segmentation of the lesion-filled 3D-T1w scans were done using Geodesic Information Flows 
23 to create cortical grey matter (CGM), deep grey matter (DGM) and normal-appearing WM 
(NAWM) masks. The brain parenchymal fraction (BPF), grey matter fraction (GMF) and WM 
fraction (WMF) were calculated, by dividing the tissue-specific volumes by the total 
intracranial volume.  
 
A fully-automated image analysis pipeline was used to determine the TSC in tissues from 
the sodium images.24 The signal intensity in calibration phantoms was used as a reference 
to quantify the TSC on a voxel-by-voxel basis.6 A series of registration steps were then used 
and concatenated to quantify TSC in each tissue type: (1) the sodium scan was registered to 
the PD/T2-weighted scan obtained using the body coil; (2) the PD/T2-weighted scan 
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obtained using the body coil was registered to the PD/T2-weighed scan obtained using the 
32-channel head coil; and (3) the PD/T2-weighted scan obtained using the 32-channel head 
coil was registered to the 3D T1-weighted scan. Tissue mask were resampled using a point-
spread-function scaling factor into sodium space to calculate the TSC (in mM) for each 
tissue.25 Using the probabilistic masks partial volume correction was performed for each 
voxel.8 Finally, using a voxel-wise partition-based correction method, we removed CSF 
contamination.8 
 
Statistical analysis 
All clinical, 1H-MRI and 23Na-MRI quantitative data are presented as mean (SD) unless 
otherwise stated.  
 
Differences in clinical measures between groups were compared using univariable linear 
regression, except for EDSS, which was compared using the non-parametric Wilcoxon rank-
sum test. Differences in 1H-MRI findings between groups were compared using univariable 
linear regression, with age and sex included as covariates when comparing brain volumetric 
measures. Differences in TSC in CGM, DGM, NAWM and lesions between groups was 
compared using univariable linear regression using GMF or WMF as a covariate depending 
on the tissue type being examined. 
 
Multivariable linear regression was used to identify independent associations between 
tissue-specific TSC and clinical measures in all patients and in the subgroup with MS. 
Significant univariable predictor variables were entered into the model and removed by 
stepwise backward manual elimination of variables with p>0.08. Each of the omitted 
variables was then tested in the final models. Because EDSS is not normally distributed, the 
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final regression model was checked using non-parametric bias-corrected and accelerated 
bootstrap with 1000 replicates to confirm associations. Tissue-specific brain atrophy was 
included as a covariate in all models, and the NART was included as a covariate in models 
examining associations with cognition. Age, sex and disease duration had no material effect 
on regression coefficients and were not retained as covariates. 
 
Statistical analyses were done using SPSS 21. Significance is reported at the level of 
p<0.05. 
 
RESULTS 
Demographic and clinical characteristics 
130 subjects were studied: 34 healthy controls and 96 patients from the CIS follow-up study 
(Table 1). Over a mean follow-up period of 14.7 years (range 11.2–19.2 years), 78 (81%) 
patients developed MS and 18 (19%) remained CIS. Among the MS patients disease course 
was classified as RRMS in 65 and SPMS in 13 patients. 20 (26%) MS patients were 
receiving (or had received) disease-modifying therapy.  
 
Compared with the patients who remained CIS at 15 years, the MS patients had more 
physical disability, worse performance on cognitive tests (with the exception of visual 
memory) and greater fatigue (p<0.05 for all comparisons). The SPMS patients had worse 
performance on all clinical measures compared with the RRMS patients (p<0.05 for all 
comparisons), except verbal memory.  
 
1H-MRI findings 
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The GMF and WMF were similar in patients who remained CIS and health controls (Table 
2). We observed significant differences in the MS patients in GMF (adjusted difference -
0.011 [95%CI -0.016, -0.006], p<0.001) and WMF (adjusted difference -0.009 [95%CI -
0.015, -0.003], p=0.002) compared with healthy controls, and significant differences in the 
MS patients in GMF (adjusted difference -0.008 [95%CI -0.014, -0.002], p=0.010) and WMF 
(adjusted difference -0.012 [95%CI -0.020, -0.004], p=0.002) compared with the CIS patients 
(Table 2). Within the MS group, the SPMS patients showed significant differences in GMF 
(adjusted difference -0.009 [95%CI -0.016, -0.001], p=0.021), WMF (adjusted difference -
0.010 [95%CI -0.020, -0.001], p=0.028), T2LV (17.97 vs 9.81 ml, p=0.026) and T1LV (5.87 
vs 1.90 ml, p<0.001) compared with RRMS patients (Table 2).  
 
23Na-MRI findings 
TSC in CGM, DGM and NAWM was similar in the patients who remained CIS and healthy 
controls (Table 2). In all MS patients together, there were significant differences in TSC in 
CGM (adjusted difference 2.12mM [95%CI 0.66, 3.57], p=0.005), DGM (adjusted difference 
1.90mM [95%CI 0.33, 3.47], p=0.018) and NAWM (adjusted difference 1.99mM [95%CI 
0.45, 3.53], p=0.012) compared with healthy controls (Table 2). These changes were driven 
by SPMS patients (Table 2).  
 
In MS patients, there were significant differences in TSC in T2-hyperintense lesions 
compared with NAWM (adjusted difference 11.42mM [95%CI 9.53, 13.3], p<0.001), and T1-
hypointense compared with T1-isointense white matter lesions (adjusted difference 8.14mM 
[95%CI 5.12, 11.17], p<0.001). Significant differences in TSC in T2-hyperintense lesions in 
the SPMS patients compared with RRMS patients (adjusted difference 7.54mM [95%CI 
2.61, 12.46], p=0.003), mainly driven by the difference in TSC in T1-isointense lesions in the 
SPMS group (adjusted difference 6.58mM [95%CI 2.29, 10.87], p=0.003) 
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Associations between tissue sodium concentrations and disability 
CGM sodium concentration was independently associated with EDSS (R2=0.26), TWT 
(R2=0.23) and 9HPT (R2=0.23) (Table 3). CGM sodium concentration was also 
independently associated with PASAT (R2=0.29), SDMT (R2=0.31), and the Brixton test 
(R2=0.36). No independent association was seen with tissue-specific TSC and memory 
tests, the Hayling test and fatigue. 
 
The multivariable linear regression analyses were repeated after excluding patients who 
remained CIS (Table 3), firstly to confirm findings in the MS group and secondly to examine 
associations between TSC in white matter lesions with disability (none of the CIS patients at 
15 years had typical demyelinating white matter lesions). In the MS-only model (n=78), CGM 
and T1-hypointense lesion TSC were associated with EDSS (R2=0.25), TWT (R2=0.24) and 
9HPT (R2=0.32). The associations with the cognitive tests was similar: CGM TSC was 
associated with PASAT (R2=0.29), SDMT (R2=0.31) and the Brixton test (R2=0.38), and no 
association was seen with memory, the Hayling test or fatigue.  
 
DISCUSSION 
In a unique, homogeneous cohort of patients with relapse-onset MS we found a consistent 
association of CGM TSC with disease course, physical disability and cognition when 
assessed cross-sectionally 15 years after disease onset. We aimed to overcome some of 
the key limitations of early applications of 23Na-MRI in MS, including: (1) an optimised 23Na-
MRI protocol with the smaller voxel sizes (effective voxel size 27 mm3 versus 64 mm3 in 
earlier studies), to reduce the impact of partial volume effects from CSF; (2) a new post-
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processing pipeline with a cutting-edge tissue segmentation algorithm23; and (3) adjustment 
of statistical analysis for tissue-specific volume loss.  
 
We found a higher TSC in both CGM and DGM in MS patients compared with healthy 
controls. In WM, a gradient was seen in MS patients with the highest TSC in T1-hypointense 
lesions, followed by T1-isointense lesions and then NAWM. These differences were mainly 
driven by patients with SPMS, who showed higher TSC in these regions compared with 
RRMS, suggesting a greater degree of neuroaxonal metabolic dysfunction, neuroaxonal 
loss, or both in SPMS. These findings are consistent with a greater extent of brain atrophy 
and microstructural damage detected using 1H-MRI in SPMS.26 27 In contrast, no increase in 
tissue-specific TSC was seen in the patients who remained CIS after 15 years. We also 
found no difference in brain volume measurements in the patients who remained CIS 
compared with healthy controls. These findings are supported by previous studies showing 
that patients who remain CIS in the long-term do not have detectable structural26 27 or 
metabolic28 abnormalities seen in people with MS, and MRI findings are similar to healthy 
controls. 
 
Independent associations were observed between 23Na-MRI abnormalities and clinical 
impairment. TSC in CGM was associated with EDSS, walking speed and upper limb 
dexterity. Previous studies have also reported an association of total grey matter TSC with 
measures of physical disability.6-8 CGM TSC was also associated with performance on tests 
of information processing speed and executive function. Cortical grey matter pathology is 
recognised as being a major substrate for both physical disability and cognitive impairment29, 
including 1H-MRI detected grey matter lesions30, atrophy27 and microstructural damage26. 
Although we observed a consistent association of CGM TSC with clinical measures, the 
associations were only moderate. This highlights that while brain 23Na-MRI is sensitive to the 
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detection of neuroaxonal metabolic changes and/or tissue loss, other disease mechanisms 
that contribute to disability and cognitive performance are not captured by this technique 
(e.g. spinal cord damage, changes in structural and functional connectivity). 
  
Sodium channel blockade has been proposed as a neuroprotective strategy in MS based on 
results of animal studies showing that sodium channel blocking agents reduced axonal loss 
in experimental autoimmune encephalomyelitis models.31 These observations are supported 
by a recent phase II showing a neuroprotective effect of phenytoin on retinal nerve fibre layer 
thinning acute optic neuritis.32 In view of our findings (and previous studies highlighting the 
sensitivity of 23Na-MRI measures of clinical impairment4-8), and the reproducibility of this 
technique (including in multi-centre studies33), TSC should be added as an exploratory 
endpoint to neuroprotection trials that aim to preserve neuroaxonal viability using sodium 
channel blockade. We have included 23Na-MRI as an endpoint in the Protective Role of 
Oxcarbazepine in Multiple Sclerosis (PROXIMUS) study – a phase IIa randomised controlled 
trial of oxcarbamazepine in people with relapsing MS with worsening disability while 
receiving disease-modifying therapies (https://clinicaltrials.gov/ct2/show/NCT02104661). 
 
Some possible limitations of this work should be noted. The healthy control group were 
younger than the patient group. However, we found no relationship between age and tissue-
specific TSC, in keeping with previous studies.8 It is unlikely that the increased TSC in MS 
patients is due to older age, particularly since there was no difference between healthy 
control and CIS patients. Although we studied a large cohort (this study is largest application 
of 23Na-MRI in MS to date), the number of patients with SPMS who were scanned as part of 
the 15 year follow-up was small (n=13). Despite the small number clear differences were 
seen, particularly in grey matter, between the SPMS and RRMS group, findings that are 
consistent with a previous study with a larger sample of patients with SPMS.8  
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Although 23Na-MRI is a promising new imaging technique with the potential to provide 
information on tissue viability, including neuroaxonal integrity and function, there are a 
number of technical challenges and limitations in previous studies using 3T clinical scanners. 
The concentration of 23Na in tissues is significantly lower than 1H with a much lower signal-
to-noise ratio. Consequently the voxel size required is significantly larger, typically 
4x4x4mm3.6-10 A larger voxel size increases the risk of partial volume effects, especially from 
CSF, which contains a much higher sodium concentration than tissues (~140mM). We took 
a number of steps to reduce the effects of partial volume, representing an innovative 
methodology. Firstly, the scans were acquired using an optimised 23Na-MRI protocol that 
included a higher resolution (nominal 3x3x3mm3) and more efficient sampling of k-space 
using a 3D-cones technique.11 These changes have been shown to improve tissue contrast, 
increase signal-to-noise ratio, and provide a better point spread function with voxel sizes 
closer to the nominal value.11 Secondly, the image-analysis pipeline included a partition-
based method to correct for CSF contamination. Thirdly, the tissue masks were resampled 
to sodium space using a point spread function scaling factor.25 Finally, as an additional 
precaution all of the analyses were adjusted for tissue-specific atrophy (GMF, WMF or both), 
which has not been done in previous studies.  
 
TSC in tissues represents a composite of intracellular and extracellular sodium. Tissue 
sodium accumulation in MS could be due to an increase in intracellular sodium due to axonal 
metabolic dysfunction, an increase in extracellular sodium due to expansion of the 
extracellular space arising from neuroaxonal loss, or both. A number of approaches have 
been described for measuring intracellular sodium concentration in vivo.  A recent study at 7 
T used triple quantum filtering to exploit the differences in the correlation time of sodium 
nuclei in intracellular and extracellular space to effectively separate them.34 This technique 
allows quantification of TSC, intracellular sodium concentration and the intracellular sodium 
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volume fraction (a surrogate measure of the extracellular sodium). This approach has been 
applied in a study of 19 patients with RRMS. Compared with healthy controls, the RRMS 
patients showed a significant increase in intracellular sodium concentration and decrease in 
intracellular sodium volume fraction.33 These findings suggest that both an increase in 
intracellular sodium concentration and a reduction in the intracellular volume (due to axonal 
loss) contribute to the increase in TSC in MS. 
 
CONCLUSIONS 
23Na-MRI detects pathological abnormalities that are relevant to long-term disease 
progression, physical disability and cognitive impairment in relapse-onset MS. Metabolic 
abnormalities in CGM may be an important mechanism contributing to disease progression 
and disease course heterogeneity in relapse-onset MS. 23Na-MRI is an emerging outcome 
measure for novel neuroprotection interventions in MS, and has started to be translated into 
neuroprotection trial design.      
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FIGURE LEGENDS 
Figure 1. Raw sodium images, sodium concentration maps, and 1H T2-weighted and T1-
weighted images (obtained using the 32 channel head coil), in healthy controls and patients 
with CIS, RRMS and SPMS. 
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Table 1 Demographic characteristics of healthy controls and patients grouped by clinical status at 15 years.  
 
   MS patients 
 Healthy 
controls 
(n=34) 
CIS patients 
(n=18) 
All MS 
(n=78) 
RRMS 
(n=65) 
SPMS 
(n=13) 
Age, years  35.5 (10.1) 49.0 (7.2) 47.0 (7.5) 46.8 (7.6) 47.8 (7.8) 
Female, n (%) 23 (66) 12 (67) 59 (86) 50 (77) 9 (69) 
Disease duration, years  14.5 (2.1) 14.7 (2.4) 14.6 (2.4) 15.0 (2.8) 
Disease-modifying therapy, n (%)  0 (0) 0 (0) 18 (28) 4 (31) 
EDSS, median (range)  0 (0-1) 2 (0-7)^^ 2 (0-6.5) 6 (3.5-7)## 
Walking speed, seconds  0.24 (0.03) 0.18 (0.06)^^ 0.20 (0.04) 0.09 (0.05)## 
9-Hole peg test, z score  0.78 (0.70) 0.23 (0.91)^ 0.50 (0.61) -1.16 (0.82)## 
Verbal memory, z | n impaired 
(%) 
 0.21 (0.60) | 0 (0) -0.32 (0.58)^^ | 1 (1) -0.27 (0.54) | 1 (2) -0.59 (0.74) | 0 (0) 
Visual memory, z | n impaired (%)  0.24 (0.49) | 0 (0) -0.06 (0.65) | 2 (3) -0.01 (0.63) | 1 (2) -0.35 (0.76)## | 1 (8) 
PASAT, z | n impaired (%)  0.21 (0.68) | 0 (0)  -0.48 (1.09)^ | 7 (9) -0.32 (0.99) | 3 (5) -1.32 (1.25)## | 4 (30) 
SDMT, z | n impaired (%)  0.31 (0.90) | 0 (0) -0.65 (1.38)^^ | 11 (14) -0.34 (1.18) | 3 (5) -2.12 (1.38)## | 8 (62) 
Brixton test, z | n impaired (%)  -0.19 (0.98) | 0 (0) -1.06 (1.18)^ | 12 (15) -0.93 (1.09) | 7 (11) -1.74 (1.44)## | 5 (38) 
Hayling test, z | n impaired (%)  0.20 (0.86) | 0 (0) -0.63 (1.04)^^ | 3 (4) -0.56 (1.01) | 1 (2) -0.97 (1.15)# | 2 (15) 
 
Fatigue severity score 
  
2.4 (1.3) 
 
4.3 (3.80)^^ 
 
3.5 (1.8) 
 
5.6 (1.5)## 
18 
 
All data presented as mean (SD) unless otherwise indicated. Impairment on cognitive tests was defined as a z score ≤2.0 standard deviations 
below published normative data.  
Abbreviations: EDSS = Expanded Disability Status Scale; PASAT = Paced Auditory Serial Addition Test; SDMT = Symbol Digit Modalities Test. 
^p<0.05 compared with CIS; ^^p<0.01 compared with CIS; #p<0.05 compared with RRMS; ##p<0.01 compared with RRMS.  
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Table 2 Total sodium concentrations in healthy controls and subjects grouped by clinical status at 15 years. 
  
Healthy controls 
(n=34) 
 
CIS patients 
(n=18) 
MS patients 
All MS 
(n=78) 
RRMS 
(n=65) 
SPMS 
(n=13) 
1H MRI      
Brain parenchymal fraction 0.768 
(0.009) 
0.767 
(0.008) 
0.747**, ^^ 
(0.028) 
0.751 
(0.018) 
       0.731## 
(0.028) 
Grey matter fraction 0.458 
(0.009) 
0.453 
(0.006) 
0.445**, ^ 
(0.014) 
0.447 
(0.012) 
      0.438## 
(0.014) 
White matter fraction 0.310 
(0.011) 
0.314 
(0.010) 
0.302**, ^^ 
(0.016) 
0.303 
(0.016) 
      0.293 ## 
(0.016) 
T2 lesion volume, ml   11.08 
(12.00) 
9.81 
(11.60) 
  17.97## 
(12.28) 
T1 lesion volume, ml   2.54 
(3.52) 
1.90 
(2.91) 
  5.87## 
(4.53) 
 
23Na MRI 
     
Cortical grey matter 40.63 mM 
(2.33)  
40.68 mM 
(1.74) 
42.82 mM** 
(3.53) 
42.30 mM 
(3.29) 
     45.45 mM# 
(3.69) 
Deep grey matter 34.83 mM 
(2.79) 
36.13 mM 
(1.69) 
36.69 mM* 
(3.74) 
36.14 mM 
(3.47) 
     39.47 mM# 
(3.98) 
Normal-appearing white matter 32.03 mM 
(3.44) 
32.92 mM 
(2.43) 
34.85 mM* 
(4.05) 
34.43 mM 
(3.95) 
  36.95 mM 
(4.04) 
White matter lesions      
     All T2-hyperintense lesions   45.58 mM 
(8.53) 
44.27 mM 
(8.27) 
  51.99 mM## 
(6.92) 
     T1-isointense lesions   43.93 mM 
(5.83) 
42.87 mM 
(7.04) 
  49.30 mM## 
(5.83) 
     T1-hypointense lesions   52.08 mM 
(7.43) 
51.02 mM 
(11.56) 
  57.45 mM  
(7.43) 
All data presented as mean (SD).  
*p<0.05 compared with healthy controls; **p<0.01 compared with healthy controls; ^p<0.05 compared with CIS; ^^p<0.01 compared with CIS; 
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#p<0.05 compared with RRMS; ##p<0.01 compared with RRMS. 
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Table 3 Statistically significant associations between tissue-specific total sodium concentrations and clinical measures 
 All patients (n=96) MS patients (n=78) 
Clinical 
measure 
TSC β 95% CI p R2      TSC β 95% CI p R2 
EDSS CGM 0.174 0.061, 0.287 0.003 0.26      CGM  
 
     T1-hypointense    
     lesions 
0.128 
 
0.020 
0.010, 0.246 
 
0.000, 0.041 
(0.002, 0.037*) 
0.035 
 
0.055 
(0.023*) 
0.25 
Walking 
speed 
CGM -0.006 -0.010, -0.002 0.003 0.23      CGM  
 
     T1-hypointense    
     lesions 
-0.005 
 
-0.001 
-0.009, -0.001 
 
-0.002, -0.0005 
0.023 
 
0.032 
0.24 
z 9HPT CGM -0.096 -0.148, -0.051 0.001 0.23      CGM  
 
     T1-hypointense    
     lesions 
-0.091 
 
-0.014 
-0.152, -0.030 
 
-0.025, -0.004 
0.004 
 
0.008 
0.32 
z PASAT CGM -0.105 -0.177, -0.032 0.005 0.29      CGM -0.101 -0.180, -0.023 0.012 0.29 
z SDMT CGM -0.156 -0.246, -0.066 0.001 0.31      CGM -0.143 -0.240, -0.046 0.005 0.31 
z Brixton test CGM -0.067 -0.120, -0.014 0.014 0.36      CGM -0.066 -0.118, -0.015 0.013 0.38 
*Bootstrap confidence interval and p-value. 
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Abbreviations: 9HPT = 9 Hole peg test; EDSS = Expanded Disability Status Scale; PASAT = Paced Auditory Serial Addition Test; SDMT = 
Symbol Digit Modalities Test. 
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